October 25-28, 2023 • Atlanta, GA
This evidence-based course is designed for the beginning/intermediate colposcopist. It will also benefit clinicians needing updated information about the newly published Updated Cervical Cancer Screening Guidelines, the Updated National Consensus Guidelines for Management of Women with Abnormal Cervical Cancer Screening Tests and Cancer Precursors, and new concepts about HPV screening and triage, treatment methods, and HPV epidemiology. This course is designed to improve competencies in medical knowledge, practice-based learning, patient outcomes, and/or systems-based practice. The participant should be a licensed physician or advanced practice clinician with an advanced clinical degree from an accredited institution and who makes gynecologic diagnosis and management decisions.
Upon completion of this educational activity, participants should be able to:
- Describe the anatomy, cytology, histology, and colposcopic findings of the normal and abnormal cervix, vagina, and vulva
- Integrate into practice the documentation of an appropriate history including risk factors for lower genital tract neoplasia
- Define the pathophysiology of lower genital tract neoplasia, including the role of oncogenic HPV in preinvasive and invasive diseases of the cervix, vagina, and vulva
- Define the Bethesda System of cervicovaginal terminology
- Apply new standards for cervical cancer screening, including HPV testing
- Describe the prevention of cervical neoplasia and genital warts using prophylactic HPV vaccines
- Discuss the challenges of colposcopy and management of cervical neoplasia for selected patient populations such as adolescents, women infected with HIV, underserved women, and pregnant women
- Perform appropriate cytologic sampling, colposcopic evaluation, and biopsies (including endocervical sampling), and become familiar with instrumentation and necessary supplies
- Apply into practice as needed the recognition of diagnostic characteristics of cervical abnormalities (low-grade and high-grade cervical lesions as well as adenocarcinoma in-situ and cervical cancer) on cytologic, colposcopic, and histologic exam
- Interpret and correlate cytologic, colposcopic, and histologic results
- Formulate a plan of care for the management of women with Pap test abnormalities according to the most recent ASCCP Consensus Guidelines, the ASCUS/LSIL Triage Study (ALTS), and other evidence-based guidelines
- Describe, but not perform, treatment options to include cryosurgery and electrosurgical loop excision procedure (LEEP) of the cervix
- Diagnose and manage vulvar and vaginal neoplasia
- Provide appropriate patient education and support
Continuing Medical Education (CME)
ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credit(s)TM
ASCCP designates this live activity for a maximum of 22.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All those who have an opportunity to control content (Faculty, Program Directors, Reviewers, Staff, etc), are required to complete a COI based on the following instructions:
ASCCP members and the general public place great trust in the work of the Society. Real or perceived undisclosed conflicts of interest may jeopardize that trust and ASCCP’s effectiveness. Conflicts of interest also may affect the objectivity of decisions that ASCCP officers and volunteers make. To minimize the potential impact of possible conflicts of interest, the Board of Directors has determined that all participants in ASCCP activities must report all real or potential conflicts prior to the activity being developed and delivered to the learners.
Additionally, the ACCME Standards for Integrity and Independence require that we disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education.
Please disclose all financial relationships that you have had in the past 24 months with ineligible companies (see definition below). For each financial relationship, enter the name of the ineligible company and the nature of the financial relationship(s). There is no minimum financial threshold; we ask that you disclose all financial relationships, regardless of the amount, with ineligible companies. You should disclose all financial relationships regardless of the potential relevance of each relationship to the education.
An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit accme.org/standards.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to ASCCP and to learners any financial relationship(s) that have occurred within the prior 24 months with any ineligible entities whose products are related to the continuing education content. Financial relationships are defined as remuneration in any amount from the ineligible entities in the form of grants, research support, consulting fees, salary, ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds), honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors, or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. ASCCP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
All of the relevant financial relationships listed for these individuals have been mitigated.
The following person(s) disclosed relevant financial relationships:
- Mark H. Einstein, MD, MS–Faculty–Dr. Einstein’s employer, Rutgers-New Jersey Medical School, has received payments for his time spent advising on or participating in educational speaking activities for Papivax, Merck, BD, and PDS Biotechnologies. Dr. Einstein has received no honorarium. Rutgers has received grant funding for research-related costs of clinical trials that he has been the overall or local PI within the past 12 months from J&J, Pfizer, Inovio, AstraZeneca, Imvax, Iovance, PDS Biotechnologies, and Becton-Dickinson. Dr Einstein is a consultant to the World Health Organization
The following person(s) disclosed no relevant financial relationships:
- Herschel W. Lawson, MD - Faculty
- Lisa Gabor, MD - Faculty
- Stacia Crochet, MD - Faculty
- Elizabeth A. Kostas-Polston, Ph.D, APRN, WHNP-BC - Faculty
- Michael Gold, MD - Author, Content Reviewer
- EJ Mayeaux, MD - Author, Content Reviewer
- Colleen Stockdale, MD - Author, Content Reviewer
- Kerry Curtis – Staff
- Cari Price – Staff
- Liesl Robinson – Staff